Kiniksa COO reports Rule 10b5-1 option exercise and share sale

Q: What insider transaction did Kiniksa (KNSA) report on this Form 4?

The Chief Operating Officer of Kiniksa Pharmaceuticals International, plc (KNSA) reported exercising a share option for 6,500 Class A ordinary shares and selling shares on 11/17/2025 .

Q: How many Kiniksa (KNSA) shares did the COO sell and at what prices?

The COO sold 645 shares at a weighted average price of $40.08 and 11,825 shares at a weighted average price of $41.30 , both through a broker in multiple trades within disclosed price ranges.

Q: What was the exercise price of the Kiniksa (KNSA) options exercised?

The share option was exercised for 6,500 Class A ordinary shares at an exercise price of $8.83 per share.

Q: Are the remaining Kiniksa (KNSA) options held by the COO vested?

The explanation notes that the option referenced is fully vested and exercisable .

Filing Impact

(Very High)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Kiniksa Pharmaceuticals International, plc (KNSA) reported an insider equity transaction by its Chief Operating Officer on Form 4. On 11/17/2025, the COO exercised a share option for 6,500 Class A ordinary shares at an exercise price of $8.83 per share, then sold shares the same day in two broker-executed transactions under a pre-arranged Rule 10b5-1 trading plan dated April 29, 2024.

The sales included 645 shares at a weighted average price of $40.08 and 11,825 shares at a weighted average price of $41.30, both executed in multiple trades within stated price ranges. After these transactions, the COO directly beneficially owned 22,714 Class A ordinary shares and held 6,000 share options that are fully vested and exercisable.

Insider Trade Summary

Exercise and sale activity reported; no spread calculated

Exercise and Sale 4 txns

Insider Tessari Eben

Role CHIEF OPERATING OFFICER

Sold 12,470 shs ($514K)

Approx. gross sale proceeds $514K

Approx. exercise cost $57K

Type	Security	Shares	Price	Value
Exercise	Share Option	6,500	$0.00	$0.00
Exercise	Class A Ordinary Share	6,500	$8.83	$57K
Sale	Class A Ordinary Share	645	$40.08	$26K
Sale	Class A Ordinary Share	11,825	$41.30	$488K

Holdings After Transaction: Share Option — 6,000 shares (Direct); Class A Ordinary Share — 22,714 shares (Direct)

Footnotes (4)

F1. This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on April 29, 2024.
F2. This transaction was executed in multiple trades through a broker-dealer at prices ranging between $39.61 and $40.585. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
F3. This transaction was executed in multiple trades through a broker-dealer at prices ranging between $40.61 and $41.60. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
F4. The option is fully vested and exercisable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 11/19/2025 - 04:38 PM

FAQ

What insider transaction did Kiniksa (KNSA) report on this Form 4?

The Chief Operating Officer of Kiniksa Pharmaceuticals International, plc (KNSA) reported exercising a share option for 6,500 Class A ordinary shares and selling shares on 11/17/2025.

How many Kiniksa (KNSA) shares did the COO sell and at what prices?

The COO sold 645 shares at a weighted average price of $40.08 and 11,825 shares at a weighted average price of $41.30, both through a broker in multiple trades within disclosed price ranges.

What was the exercise price of the Kiniksa (KNSA) options exercised?

The share option was exercised for 6,500 Class A ordinary shares at an exercise price of $8.83 per share.

How many Kiniksa (KNSA) shares and options does the COO own after the transaction?

Following the reported transactions, the COO directly beneficially owned 22,714 Class A ordinary shares and 6,000 share options.

Was the Kiniksa (KNSA) insider sale under a Rule 10b5-1 trading plan?

Yes. The filing states that the transactions were effected pursuant to a Rule 10b5-1 trading plan executed by the reporting person on April 29, 2024.

Are the remaining Kiniksa (KNSA) options held by the COO vested?

The explanation notes that the option referenced is fully vested and exercisable.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Tessari Eben

(Last)

(First)

(Middle)

C/O KINIKSA PHARMACEUTICALS INTERNATIONA

105 PICCADILLY, SECOND FLOOR

(Street)

LONDON

W1J 7NJ

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Kiniksa Pharmaceuticals International, plc [ KNSA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	CHIEF OPERATING OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
11/17/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Class A Ordinary Share	11/17/2025		M⁽¹⁾		6,500	A	$8.83	35,184	D
Class A Ordinary Share	11/17/2025		S⁽¹⁾		645	D	$40.08⁽²⁾	34,539	D
Class A Ordinary Share	11/17/2025		S⁽¹⁾		11,825	D	$41.3⁽³⁾	22,714	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Share Option	$8.83	11/17/2025		M⁽¹⁾			6,500	⁽⁴⁾	09/16/2029	Class A Ordinary Share	6,500	$0	6,000	D

Explanation of Responses:

1. This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on April 29, 2024.

2. This transaction was executed in multiple trades through a broker-dealer at prices ranging between $39.61 and $40.585. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.

3. This transaction was executed in multiple trades through a broker-dealer at prices ranging between $40.61 and $41.60. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.

4. The option is fully vested and exercisable.

	/s/ Douglas Barry, Attorney-in-Fact	11/19/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR